Pharmaceutical Executive
Reshaping Pharmacovigilance in the age of AI
Jan 4, 2024
Sameer Lal, Sr. Vice President at Indegene, shares his extensive knowledge in pharmacovigilance and AI from his 27 years in the industry. He talks about a new study illustrating customer perspectives on pharmacovigilance and the challenges in adopting AI technologies, revealing only 5% of organizations have done so. Lal emphasizes AI's potential to enhance data analysis and customer engagement while encouraging upskilling in the workforce. He also compares generative AI's impact on pharma to major tech revolutions, marking an exciting future for innovation.
17:00
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The integration of AI in pharmacovigilance is still in its infancy, with only 5% of organizations currently adopting these technologies despite significant potential benefits.
- Generative AI is expected to transform the pharmaceutical industry by automating repetitive tasks, allowing employees to focus on strategic initiatives and fostering a culture of innovation.
Deep dives
The Shift in Pharmacovigilance with AI
Pharmacovigilance, or drug safety monitoring, is undergoing a significant transformation due to advancements in artificial intelligence. A recent study indicated that only 5% of organizations have implemented AI technologies in their pharmacovigilance practices. Key barriers include the previously inadequate development of technology and resistance to change within organizations, as employees are accustomed to established workflows. However, as technology improves, companies are starting to embrace these changes, and it is anticipated that the adoption rate will significantly increase in the near future.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
